PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Recruiting now · Phase 2

Conditions studied: Inborn Errors of Immunity

In brief

The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)

Key facts

Study ID

NCT06199427

Run by

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

People needed

100

Starts

2023-11-21

Expected to finish

2027-12-31

Last updated by the study team

2024-01-10

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged ≥ 0 months and < 21 years
• Patients diagnosed with NBS eligible for an allogeneic HSCT
• Signed written informed consent signed by a parent or legal guardian

You may not qualify if…

• Concomitant severe somatic disease associated with an additional risk of severe complications

Where it is running

• HSCT department — Moscow, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.